CYP2D6-inhibiting antidepressants linked to worse outcomes than CYP2D6-neutral antidepressants when used with CYP2D6-metabolizing opioids
Higher risk seen for gaining weight with escitalopram, paroxetine, duloxetine; lower risk with bupropion
Higher frequencies of discontinuation symptoms seen in association with desvenlafaxine, venlafaxine, imipramine, and escitalopram
Bipolar diagnosis substantially cuts inpatient care in all age groups, which coincided with drop in antidepressant use
Authors find 19 percent increased risk for antidepressant Rx among previously naive adults
Rate increased by 17.0 percent per month before March 2020; increased 63.5 percent faster from March 2020 onward
Findings based on neuroimaging and clinical data can speed knowledge of efficacy to one week
Sex differences seen, with women experiencing greater antidepressant use and less reduction in use
Pharmacogenomic testing predicted to save the health system $956 million and bring health gains of 0.381 QALYs per patient
Reduction in need for anxiolytic drugs, antidepressants strongest for men and young and middle-aged adults